CF
LXEO icon

Corebridge Financial’s Lexeo Therapeutics LXEO Stock Holding History

Corebridge Financial’s Portfolio LXEO Stock Details LXEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-11,544
Closed -$40.1K – 1578
2025
Q1 		$40.1K Sell
11,544
-171
-1% -$758 ﹤0.01% 2786
2024
Q4 		$77.1K Sell
11,715
-885
-7% -$6.97K ﹤0.01% 2673
2024
Q3 		$114K Buy
12,600
+7,093
+129% +$84.6K ﹤0.01% 2553
2024
Q2 		$88.3K Buy
+5,507
New +$80K ﹤0.01% 2660

Other funds holding LXEO

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Corebridge Financial's LXEO Position: Q2 2025 in Review

Corebridge Financial sold out of Lexeo Therapeutics (LXEO) in Q2 2025, closing a stake of 11,544 shares — an estimated $40.1K sold.

Corebridge Financial first reported a position in LXEO in Q2 2024 and held it in 4 quarters. The position peaked at $114K in Q3 2024. 90 funds tracked by Wall St. Rank hold LXEO as of Q2 2025.

  • Corebridge Financial reported no remaining Lexeo Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Corebridge Financial sold 11,544 Lexeo Therapeutics shares in Q2 2025, an estimated $40.1K.
  • Corebridge Financial first reported a position in Lexeo Therapeutics in Q2 2024 and held it in 4 quarters.
  • Corebridge Financial's Lexeo Therapeutics position peaked at $114K in Q3 2024.
  • 90 funds tracked by Wall St. Rank held Lexeo Therapeutics as of Q2 2025.

Based on Corebridge Financial's 13F filing for Q2 2025, filed 12 Aug 2025.